1. Zura Bio will present at Jefferies Global Healthcare Conference on June 4, 2025. 2. Zura’s pipeline includes dual-pathway antibodies for autoimmune diseases. 3. Lead candidate tibulizumab is in Phase 2 trials for systemic sclerosis and hidradenitis suppurativa. 4. One-on-one investor meetings will occur during the conference.
The upcoming conference provides visibility for Zura Bio and its pipeline. Successful presentations can attract investments and positively influence stock prices, similar to past biotech presentations leading to significant stock gains.
The announcement about the presentation boosts investor interest and engagement with Zura’s pipeline, likely driving momentum and reinforcing investor confidence in the company's growth trajectory.
The Jefferies conference occurs soon, likely influencing investor sentiment immediately. Previous events show rapid impacts on stock prices post-news or presentations.
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present a corporate overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 3:10 PM ET in New York, NY. In addition, the Company will participate in one-on-one meetings with investors during the conference.
A live webcast of the presentation will be available on the News & Events page in the Investors section of the Zura Bio website. A replay will be accessible following the event and will remain archived on the website for at least 30 days.
ABOUT ZURA BIO
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases. The Company’s pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.
Zura Bio’s lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.
For more information, please visit www.zurabio.com.